On September 2nd, OMass Therapeutics announced it has entered into an exclusive collaboration and licensing agreement with Genentech, a member of the Roche Holding Ltd (RHHBY.US) group, granting the latter rights to develop and commercialize OMass's preclinical oral small molecule program targeting inflammatory bowel disease (IBD). OMass is a biotechnology company focused on developing drugs against highly validated target ecosystems such as membrane proteins or intracellular complexes. Under the agreement terms, OMass will receive an upfront payment of $20 million, with potential milestone payments exceeding $400 million covering preclinical, development, commercial, and net sales milestones. OMass is also eligible for tiered royalties based on net sales. Under this collaboration, OMass will lead the initial preclinical development of the program until candidate selection. Genentech will be responsible for clinical development, regulatory filings, manufacturing, and commercialization activities.